Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock
Spyre Therapeutics CEO Cameron Turtle sold 14,000 shares ($1.38m) of SYRE stock on October 1, 2026, under a 10b5-1 plan. He retains 537,540 shares. SYRE's stock surged 487% in the past year but is deemed overvalued. Recent Phase II trial results showed mixed efficacy, leading to a stock decline. Analysts maintain Buy ratings with targets ranging from $110 to $130.
How this was made
The 30-second read
Why it matters
The insider sale adds a negative catalyst that could temper the recent rally.
Market read
Primary insider‑sale disclosure for a high‑growth biotech; modest trading relevance.
What to watch
Recent positive trial data and analyst upgrades may offset the negative signal from the sale.
Background
Spyre Therapeutics (SYRE) has recently reported mixed Phase II trial results and received several analyst upgrades, while its stock has surged 487% over the past year.
Ticker impact
CEO Cameron Turtle sold 14,000 shares for about $1.38 million under a 10b5‑1 plan, a primary insider‑sale disclosure.
potential downward pressure as the market prices in the insider sale
Insider sales often trigger short‑term selling pressure, especially after a large price surge.
Market effects
Limited; biotech sector may see modest scrutiny of insider activity.
US market only, no broader regional effect.
Low; the news is company‑specific.
Counterpoint
The sale could be routine under a pre‑approved plan and not reflect lack of confidence.
Key entities
- companySpyre Therapeutics, Inc.
Biotech firm developing inflammatory disease therapies.
- executiveCameron Turtle
CEO and director of Spyre Therapeutics.
